Healthcare Apr 26, 2022 11:20 AM (GMT+8) · EqualOcean
Recently, Shionogi, a Japanese pharmaceutical company, announced at the European Conference on clinical microbiology and infectious diseases that the drug II B study results showed a "quick clearance" for COVID-19. Yanyeyi's new crown medicine s-217622 was jointly developed by Hokkaido University and yanyeyi. The drug principle is similar to Pfizer's new crown medicine paxlovid, which inhibits virus self replication by inhibiting 3CL protease activity. Yanye also claimed that after structural improvement, s-217622 can get rid of its dependence on P450 enzyme inhibitors (such as ritonavir) and realize the new crown of single drug treatment. Previously, s-217622 was exposed to teratogenic risk. Animal experiments of the drug show that the drug may cause abnormal fetal bone development and may cause teratogenesis. It is reported that yanye Yizheng is considering not recommending the drug to pregnant women.

This text is a result of machine translation.